Various pharmaceutical products / 2024-2025
Finnish Institute for Health and Welfare · koko Suomi
Perustiedot
- Tarjousten määräaika
- pe 3.5.2024 klo 12.00 (päättynyt)
- Siirtyi muutosilmoituksella 14.4. (oli 26.4. klo 12.00)
- Kysymysten määräaika
- pe 19.4.2024 klo 12.00 (päättynyt)
- Hankkija
- Finnish Institute for Health and Welfare, Y-tunnus 2229500-6
- Toteutuspaikka
- koko Suomi
- Hankintalaji
- Tavarahankinta
- Menettely
- Avoin menettely, EU-hankinta
- Ilmoituksen tyyppi
- Hankintailmoitus
- Arvioitu kokonaisarvo
- Ei ilmoitettu
- Erät
- 15 erää
- Pääasiallinen CPV
- 33600000 Farmaseuttiset tuotteet
- Sopimuskausi
- 13 kuukautta
- Julkaistu
- 24.3.2024 · muutettu 14.4.2024
- Muutosilmoitus: Ostajan virheen korjaaminen
Ilmoituksen teksti
Alkuperäinen teksti Hilmasta, muuttamattomanaFinnish Institute for Health and Welfare, later referred to as THL or Customer, request your tender for Various pharmaceutical products to the rescEU project. The Scope of procurement is described in more detail in Annex 1.
The procurement is divided in fifteen (15) lots. Each product constitutes a separate lot. Tender may be submitted for one or several lots.
- LOT 1: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01)
- LOT 2: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01)
- LOT 3: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01)
- LOT 4: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09)
- LOT 5: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24)
- LOT 6: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01)
- LOT 7: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08)
- LOT 8: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02)
- LOT 9: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02)
- LOT 10: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02)
- LOT 11: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01)
- LOT 12: Meropenem 500-1000 mg per vial/ampoule, i.v. (ATC J01DH02)
- LOT 13: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01)
- LOT 14: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02)
- LOT 15: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16)
The minimum requirements for the products is described in Annex 1.1.
The Contract will be awarded to one Supplier for each lot based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
The contract period shall enter into force once the contract has been signed by Contracting parties and expires when all contractual duties of the Contract have been performed.
Estimated quantity for the products is described in Annex 6 (restricted to security classification level IV, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Supplier is not obliged to deliver the products under the Option.
Please note that all times given in the Call for tenders refer to local time in Finland.
Call for tenders, Annexes:
Annex 1 Scope of the procurement
Annex 1.1 Minimum requirements
Annex 2 Contract
Annex 3 Security annex
Annex 4 JYSE 2014 SUPPLIES (updated version of April 2022)
Annex 5 Confidentiality commitment
Annex 6 Estimated quantity (restricted, TL IV)
Please note that the numbering of the annexes differs between the Contract and the Call for tenders.
Lisätiedot
The availability for the Annex 6 is restricted to security classification level IV (TL IV). THL will send the Annex 6 to a representative of the tenderer via encrypted e-mail after THL has received a scanned version of the signed confidentiality commitment (Annex 5). The signature of the confidentiality commitment shall be done manually by hand. Confidentiality commitment shall be signed by a legal representative of tenderer. Confidentiality commitment shall be sent to the e-mail address kirjaamo@thl.fi with the subject line "CONFIDENTIALITY COMMITMENT - THL/1198/2.02.06/2024 / Various pharmaceutical products". The message shall contain name of the tenderer and e-mail address to which the Annex 6 is to be sent.
Muutoksen syy
The contracting entity has incorrectly indicated the formation of the reference price for lot 8 and lot 15. As an exception to the other lots, the reference price for subdivisions 8 and 15 is not based on the quantity of active pharmaceutical ingredient (API). For lot 8, the reference price is constructed based on the total quantity of doses, and for lot 15, the reference price is constructed based on the total volume of the Article. The total quantities of Articles are correctly indicated in the original Annex 6 Estimated quantity (restricted, TL IV).
Due to this correction, the deadline for receiving tenders will be extended and the deadline for questions related to the procurement will be extended.
Muutoksen kuvaus
Award criterion 1
Original:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the quantity of single units (tablets, vials etc.) that is needed to comply with the announced active pharmaceutical ingredient (API) total quantity described in the Annex 6 (Estimated quantity, TL IV). The offered price includes the Articles and transport according to the call for tenders and covers all requirements set out in the Call for Tenders and it's Annexes.
Corrected:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the quantity of single units (inhaler) that is needed to comply with the announced total quantity of doses described in the Annex 6 (Estimated quantity, TL IV). The offered price includes the Articles and transport according to the call for tenders and covers all requirements set out in the Call for Tenders and it's Annexes.
Muutoksen kuvaus
Award criteria 1
Original:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the quantity of single units (tablets, vials etc.) that is needed to comply with the announced active pharmaceutical ingredient (API) total quantity described in the Annex 6 (Estimated quantity, TL IV). The offered price includes the Articles and transport according to the call for tenders and covers all requirements set out in the Call for Tenders and it's Annexes.
Corrected:
The reference price of the tender consists of the total price of the offered Articles. The total price shall be based on the quantity of single units (vial/ampoule) that is needed to comply with the announced total volume described in the Annex 6 (Estimated quantity, TL IV). The offered price includes the Articles and transport according to the call for tenders and covers all requirements set out in the Call for Tenders and it's Annexes.
Erien kuvaukset
Erä 1: LOT 1: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01)
- Intramuscular administration
- Active pharmaceutical ingredient: Morphine
- Strength: 10-20 mg/ml
- Pharmaceutical form: 1-5 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 2: LOT 2: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01)
- Intramuscular administration and intravenous administration
- Active pharmaceutical ingredient: Ondansetron
- Strength: 2 mg/ml
- Pharmaceutical form: 2-4 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 3: LOT 3: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01)
- Oral solid dosage form
- Active pharmaceutical ingredient: Ondansetron
- Strength: 4-8 mg per tablet/capsule
- Pharmaceutical form: tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 4: LOT 4: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09)
- Powder for solution,, intravenous administration
- Active pharmaceutical ingredient: Hydrocortisone
- Strength: 250 mg / 2 ml
- Pharmaceutical form: 2 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 5: LOT 5: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24)
- Intravenous administration and intramuscular administration
- Active pharmaceutical ingredient: Epinephrine (Adrenaline)
- Strength: 1 mg/ml
- Pharmaceutical form: 1-5 ml per vial/ampoule, the label shall include inhaling use in addition
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 6: LOT 6: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01)
- Intramuscular administration and intravenous administration
- Active pharmaceutical ingredient: Diazepam
- Strength: 10 mg / 2 ml
- Pharmaceutical form: 2 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 7: LOT 7: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08)
- Intravenous administration
- Active pharmaceutical ingredient: Midazolam
- Strength: 1-5 mg/ml
- Pharmaceutical form: 3-10 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 8: LOT 8: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02)
- Inhalation
- Active pharmaceutical ingredient: Salbutamol
- Strength: 200 µg/dose
- Pharmaceutical form: 60 or 200 doses per inhaler
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 9: LOT 9: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02)
- Inhalation
- Active pharmaceutical ingredient: Budesonide
- Strength: 0,5 mg/ml
- Pharmaceutical form: 2 ml nebuliser suspension per respule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 10: LOT 10: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02)
- Intravenous administration
- Active pharmaceutical ingredient: Ciprofloxacin
- Strength: 2 mg/ml
- Pharmaceutical form: 100-200 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 11: LOT 11: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01)
- Powder for solution, intramuscular administration
- Active pharmaceutical ingredient: Streptomycin
- Strength: 1 g per vial/ampoule
- Pharmaceutical form: vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 12: LOT 12: Meropenem 500-1000 mg per vial/ampoule, i.v. (ATC J01DH02)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Meropenem 500-1000 mg per vial/ampoule, i.v. ( ATC J01DH02)
- Powder for solution, intravenous administration
- Active pharmaceutical ingredient: Meropenem
- Strength: 500-1000 mg per vial/ampoule
- Pharmaceutical form: vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 13: LOT 13: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01)
- Intramuscular administration and intravenous administration
- Active pharmaceutical ingredient: Clindamycin
- Strength: 600 mg / 4 ml
- Pharmaceutical form: 4 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 14: LOT 14: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02)
- Oral solid dosage form
- Active pharmaceutical ingredient: Ciprofloxacin
- Strength: 250-500 mg per tablet/capsule
- Pharmaceutical form: tablet/capsule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erä 15: LOT 15: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16)
The subject of the procurement is Article in accordance with the following requirements:
- The subject of tender: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16)
- Intravenous administration
- Active pharmaceutical ingredient: Ethanol
- Strength: 95-96 %
- Pharmaceutical form: 5-20 ml per vial/ampoule
The minimum requirements of the Article is described in more detail in Annex 1.1.
The delivery schedule for the articles is described in Annex 1.
Estimated quantity for the Article is described in Annex 6 (restricted, TL IV). In addition to the estimated quantity indicated in the Annex 6, the Customer is entitled to purchase 100 % extra to the estimated quantities (later referred as "Option"). The Customer can use as much of the option as it needs. The Customer shall notify the Supplier by the end of June 2026 at the latest, if it wishes to exercise the Option. The delivery schedule for the Option will be agreed separately between the Contracting parties. The Supplier is not obliged to deliver the Articles under the Option.
The Contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.
Erät
| Erä | Nimi | Ammattiala | Arvioitu arvo | CPV |
|---|---|---|---|---|
| 1 | LOT 1: Morphine 10-20 mg/ml (1-5 ml per vial/ampoule, i.m., ATC N02AA01) Ratkaistu | – | – | 33661200, 33600000 |
| 2 | LOT 2: Ondansetron 2 mg/ml (2-4 ml per vial/ampoule, i.m. and i.v., ATC A04AA01) Ratkaistu | – | – | 33600000 |
| 3 | LOT 3: Ondansetron 4-8 mg per tablet/capsule, oral (ATC A04AA01) Keskeytetty | – | – | 33600000 |
| 4 | LOT 4: Hydrocortisone 250 mg / 2 ml (2 ml per vial/ampoule i.v., ATC H02AB09) Ratkaistu | – | – | 33642200, 33600000 |
| 5 | LOT 5: Epinephrine (Adrenaline) 1 mg/ml (1-5 ml per vial/ampoule, i.v. and i.m., ATC C01CA24) Ratkaistu | – | – | 33600000 |
| 6 | LOT 6: Diazepam 10 mg / 2 ml (2 ml per vial/ampoule, i.m. and i.v., ATC N05BA01) Ratkaistu | – | – | 33600000 |
| 7 | LOT 7: Midazolam 1-5 mg/ml (3-10 ml per vial/ampoule, i.v., ATC N05CD08) Ratkaistu | – | – | 33600000 |
| 8 | LOT 8: Salbutamol 200 µg/dose (inhaler, 60 or 200 doses, ATC R03AC02) Ratkaistu | – | – | 33670000, 33600000 |
| 9 | LOT 9: Budesonide 0,5 mg/ml (2 ml nebuliser suspension per respule, ATC R03BA02) Keskeytetty | – | – | 33670000, 33600000 |
| 10 | LOT 10: Ciprofloxacin 2 mg/ml (100-200 ml per vial/ampoule, i.v., ATC J01MA02) Ratkaistu | – | – | 33651100, 33600000 |
| 11 | LOT 11: Streptomycin 1 g per vial/ampoule, i.m. (ATC J01GA01) Keskeytetty | – | – | 33651100, 33600000 |
| 12 | LOT 12: Meropenem 500-1000 mg per vial/ampoule, i.v. (ATC J01DH02) Ratkaistu | – | – | 33651100, 33600000 |
| 13 | LOT 13: Clindamycin 600 mg / 4 ml (4 ml per vial/ampoule, i.m. and i.v., ATC J01FF01) Ratkaistu | – | – | 33651100, 33600000 |
| 14 | LOT 14: Ciprofloxacin 250-500 mg per tablet/capsule, oral (ATC J01MA02) Ratkaistu | – | – | 33651100, 33600000 |
| 15 | LOT 15: Ethanol 95-96 % (5-20 ml per vial/ampoule, i.v., ATC V03AB16) Keskeytetty | – | – | 33690000, 33600000 |
Hankinnan vaiheet
-
Hankintailmoitus
Tarjouspyyntö julkaistiin, määräaika 26.4.2024 klo 12.00.
-
Muutosilmoitustämä ilmoitus
Määräaika siirtyi 3.5.2024 klo 12.00.
-
Voittajat: Grindeks Kalceks Suomi Oy, Pfizer Oy, FrostPharma AB ja 2 muuta.